Department of Clinical Laboratory, Saitama Medical University Hospital, Saitama, Japan.
Department of Infectious Disease and Infection Control, Saitama Medical University, Saitama, Japan.
Diagn Microbiol Infect Dis. 2021 Jul;100(3):115370. doi: 10.1016/j.diagmicrobio.2021.115370. Epub 2021 Mar 13.
Several automated high-throughput immunoassays for detecting anti-SARS-CoV-2 antibodies by a semi-quantitative approach have been commercialized. In this study, we describe the timeline of the antibody response in patients with RT-PCR-confirmed COVID-19. A total of 292 sequential serum samples from 33 Japanese patients were retrospectively analyzed using four test kits for SARS-CoV-2: the Abbott SARS-CoV-2 IgG assay (Abbott), Elecsys® Anti-SARS-CoV-2 assay (Roche Diagnostic), and VITROS® Anti-SARS-CoV-2 Total and IgG assays (Ortho Clinical Diagnostics). All automated immunoassays could equivalently identify positive sera collected within 2 weeks after symptom onset (99.3%-100%). In addition, the S protein-based automated immunoassay, the VITROS® Anti-SARS-CoV-2 Total assay, may play a complementary role in evaluating passive antibody therapies or vaccines against SARS-CoV-2, although further research is required.
已经有几种用于通过半定量方法检测抗 SARS-CoV-2 抗体的自动化高通量免疫测定法被商业化。在这项研究中，我们描述了经 RT-PCR 确诊的 COVID-19 患者的抗体反应时间过程。使用 Abbott SARS-CoV-2 IgG 测定试剂盒（Abbott）、Elecsys® Anti-SARS-CoV-2 测定试剂盒（罗氏诊断）和 VITROS® Anti-SARS-CoV-2 总抗体和 IgG 测定试剂盒（奥森多临床诊断），对 33 名日本患者的 292 份连续血清样本进行了回顾性分析。所有的自动化免疫测定法都可以等效地识别在症状出现后 2 周内采集的阳性血清（99.3%-100%）。此外，基于 S 蛋白的自动化免疫测定法，即 VITROS® Anti-SARS-CoV-2 总抗体测定法，可能在评估针对 SARS-CoV-2 的被动抗体疗法或疫苗方面发挥补充作用，尽管需要进一步的研究。
